Peran Reseptor IL-21 (IL-21R) sebagai Target Terapi Pada Penyakit Arteri Perifer

Authors

  • Muhammad Luthfi Adnan Program Studi Pendidikan Profesi Dokter, Fakultas Kedokteran, Universitas Islam Indonesia, Sleman

DOI:

https://doi.org/10.32734/scripta.v3i1.4440

Keywords:

interleukin-21 receptors, peripheral artery disease, therapy, penyakit arteri perifer, reseptor interleukin-21, terapi

Abstract

Background: Peripheral Artery Disease (PAD) is caused due to the disruption of blood supply to the periphery caused by blockages in the arteries. PAD is a disease that is difficult to detect and the current therapy is still limited to pharmacological therapy to reduce the risk of PAP incidence and surgical therapy if complications of PAD arise. The interleukin-21 receptor (IL-21R) is a family of interleukins that has been widely studied for its role in many diseases.

Objectives: The aim of this review is to discuss the effect of IL-21R on the pathogenesis of PAP.

Methods: A literature search was performed with PubMed, Google Scholar, and ScienceDirect using the keywords “peripheral artery diseaseâ€, “interleukin-21 receptorâ€, “inflammationâ€, “angiogenesisâ€, and “therapyâ€.

Discussion: PAD can arise due to the formation of atherosclerotic plaques that block arteries so that blood supply is impaired. In the case of PAD, activation of IL-21R has the ability to stimulate angiogenesis thereby modulating the perfusion of hypoxic tissues in cases of PAD. Further research is needed regarding IL-21R activity in the future to study the potential of IL-21R for the more effective treatment of PAD cases in the future.

Conclusion: IL-21R can activate angiogenesis and avoid further tissue damage in PAP.

Keywords: interleukin-21 receptors, peripheral artery disease, therapy

 

Latar Belakang: Penyakit Arteri Perifer (PAP) disebabkan karena gangguan suplai darah ke bagian perifer yang disebabkan karena sumbatan pada pembuluh darah arteri. PAP merupakan penyakit yang sulit terdeteksi dan terapi yang ada saat ini masih terbatas pada terapi farmakologis untuk menurunkan risiko kejadian PAP dan terapi pembedahan apabila timbul komplikasi PAP. Reseptor interleukin-21 (IL-21R) merupakan salah satu famili interleukin yang telah banyak dipelajari terkait perannya pada banyak penyakit.

Tujuan: Tujuan dari tinjauan ini adalah untuk membahas pengaruh IL-21R terhadap perjalanan penyakit PAP.

Metode: Pencarian literatur dilakukan dengan PubMed, Google Scholar, dan ScienceDirect menggunakan kata kunci “peripheral artery diseaseâ€, “reseptor interleukin-21â€, “inflamasiâ€, â€angiogenesisâ€, dan “terapiâ€.

Pembahasan: PAP dapat timbul karena pembentukan plak aterosklerosis yang menyumbat pembuluh darah arteri sehingga suplai darah terganggu. Pada kasus PAP, aktivasi IL-21R memiliki kemampuan untuk menstimulasi angiogenesis sehingga memodulasi perfusi jaringan yang mengalami hipoksia pada kasus PAP. Masih diperlukan penelitian lebih lanjut mengenai aktivitas IL-21R di masa depan untuk mempelajari potensi IL-21R untuk pengobatan kasus PAP yang lebih efektif di masa depan.

Kesimpulan: IL-21R dapat mengaktivasi angiogenesis dan menghindari kerusakan jaringan lebih lanjut pada PAP.

Kata Kunci: penyakit arteri perifer, reseptor interleukin-21, terapi

Downloads

Download data is not yet available.
Cover SCRIPTA Vol 3 No 1

Published

2021-08-28

How to Cite

1.
Adnan ML. Peran Reseptor IL-21 (IL-21R) sebagai Target Terapi Pada Penyakit Arteri Perifer. SCRIPTA SCORE Sci Med J. [Internet]. 2021Aug.28 [cited 2024Dec.22];3(1):68-75. Available from: https://talenta.usu.ac.id/scripta/article/view/4440

Issue

Vol. 3 No. 1 (2021): SCRIPTA SCORE Scientific Medical Journal

Section

Review Article

Copyright (c) 2021 Muhammad Luthfi Adnan

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with SCRIPTA SCORE Scientific Medical Journal agree to the following terms:

  1. Authors retain copyright and grant SCRIPTA SCORE Scientific Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in SCRIPTA SCORE Scientific Medical Journal.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in SCRIPTA SCORE Scientific Medical Journal.